Amyris, Antibioticos Enter Contract Mfg. Pact

Amyris, Inc. has entered into a contract manufacturing agreement with Antibióticos, S.A. to produce farnesene at Antibióticos’ facilities in León, Spain. The farnesene product will be owned and distributed by Amyris. The two companies began testing fermentation production runs in January 2011, and following the successful outcome, are proceeding with expanded production.

“This agreement with Antibióticos should allow us to reach our target initial production levels and meet customer demand for our near-term product offerings,” said John Melo, chief executive officer of Amyris. “We have been very impressed with the world-class technical expertise in aseptic fermentation at Antibióticos, and are looking forward to leverage this as we build up our commercial production capability.”

“This agreement merges our experience and technical capacity with Amyris’s technology and processes, and forms another important step in the strategy of diversifying our business portfolio,” said Daniele Pucci Di Benisichi, chief executive officer of Antibióticos. “Our initial work with Amyris has validated their technology in our facility. Additionally, we see a strong match between the two companies’ values and vision. Antibióticos follows a very demanding and selective approach for new projects, and we are proud to use this cutting-edge technology.”